PharmaResources (Shanghai) Past Earnings Performance
Past criteria checks 1/6
PharmaResources (Shanghai) has been growing earnings at an average annual rate of 10.4%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 18.9% per year. PharmaResources (Shanghai)'s return on equity is 2.4%, and it has net margins of 5.2%.
Key information
10.4%
Earnings growth rate
-0.9%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 18.9% |
| Return on equity | 2.4% |
| Net Margin | 5.2% |
| Next Earnings Update | 28 Aug 2024 |
Revenue & Expenses Breakdown
How PharmaResources (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 499 | 26 | 78 | 38 |
| 31 Dec 23 | 490 | 38 | 74 | 37 |
| 30 Sep 23 | 514 | 75 | 71 | 39 |
| 30 Jun 23 | 511 | 80 | 70 | 38 |
| 31 Mar 23 | 496 | 72 | 80 | 35 |
| 01 Jan 23 | 479 | 67 | 80 | 33 |
| 30 Sep 22 | 485 | 72 | 79 | 30 |
| 30 Jun 22 | 465 | 72 | 77 | 26 |
| 31 Mar 22 | 458 | 73 | 64 | 22 |
| 01 Jan 22 | 448 | 74 | 64 | 17 |
| 30 Sep 21 | 377 | 48 | 61 | 12 |
| 31 Dec 20 | 283 | 49 | 43 | 12 |
| 31 Dec 19 | 245 | 47 | 37 | 10 |
| 30 Jun 19 | 171 | 30 | 35 | 10 |
| 31 Mar 19 | 149 | 19 | 35 | 9 |
| 31 Dec 18 | 126 | 8 | 35 | 8 |
| 30 Sep 18 | 127 | 10 | 27 | 15 |
| 30 Jun 18 | 127 | 11 | 25 | 16 |
| 31 Mar 18 | 131 | 16 | 30 | 13 |
| 31 Dec 17 | 135 | 20 | 34 | 10 |
| 30 Sep 17 | 131 | 20 | 38 | 5 |
| 30 Jun 17 | 127 | 19 | 41 | 0 |
| 31 Mar 17 | 117 | 16 | 40 | 0 |
| 31 Dec 16 | 107 | 14 | 38 | 0 |
| 30 Sep 16 | 95 | 11 | 36 | 0 |
| 30 Jun 16 | 84 | 9 | 35 | 0 |
| 31 Mar 16 | 80 | 7 | 34 | 0 |
| 01 Jan 16 | 76 | 6 | 32 | 0 |
Quality Earnings: 301230 has a high level of non-cash earnings.
Growing Profit Margin: 301230's current net profit margins (5.2%) are lower than last year (14.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301230's earnings have grown by 10.4% per year over the past 5 years.
Accelerating Growth: 301230's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301230 had negative earnings growth (-63.9%) over the past year, making it difficult to compare to the Life Sciences industry average (0.7%).
Return on Equity
High ROE: 301230's Return on Equity (2.4%) is considered low.